| |
Periodic table of the elements science and academic information, elements and advanced materials data, scientific presentations and all pages, designs, concepts, logos, and color schemes herein are the copyrighted proprietary rights and intellectual property of American Elements. American Elements is a U.S. Registered Trademark. © 2001-2009. American Elements. All rights reserved. |
 |
|
Recent Research & Development for Gadolinium
-
Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.
Galldiks N, Ullrich R, Schroeter M, Fink GR, Kracht LW.
Eur J Nucl Med Mol Imaging. 2009 Aug 7. [Epub ahead of print]
PMID: 19662410 [PubMed - as supplied by publisher]
- [MRI exploration for the evaluation of orbital implant biocolonization in children enucleated for retinoblastoma.]
Douira-Khomsi W, Korchane N, Louati H, Bhouri L, Kchaou I, Ben Hassine L, Bouguila H, Ayed S, Bellagha I.
J Fr Ophtalmol. 2009 Aug 4. [Epub ahead of print] French.
PMID: 19660832 [PubMed - as supplied by publisher]
- Magnetic resonance imaging of mesenchymal stem cells labeled with dual (MR and fluorescence) agents in rat spinal cord injury.
Shen J, Zhong XM, Duan XH, Cheng LN, Hong GB, Bi XB, Liu Y.
Acad Radiol. 2009 Sep;16(9):1142-54.
PMID: 19660710 [PubMed - in process]
- Cerebral ischemia-reperfusion injury in rats-A 3 T MRI study on biphasic blood-brain barrier opening and the dynamics of edema formation.
Pillai DR, Dittmar MS, Baldaranov D, Heidemann RM, Henning EC, Schuierer G, Bogdahn U, Schlachetzki F.
J Cereb Blood Flow Metab. 2009 Aug 5. [Epub ahead of print]
PMID: 19654585 [PubMed - as supplied by publisher]
- Dynamic Contrast-Enhanced Perfusion MR Imaging With SPIO: A Pilot Study.
Amemiya S, Akahane M, Aoki S, Abe O, Kamada K, Saito N, Ohtomo K.
Invest Radiol. 2009 Jul 31. [Epub ahead of print]
PMID: 19652616 [PubMed - as supplied by publisher]
- [Spectroscopic analysis of Nd:GGG laser crystal]
Zeng FM, Zhang Y, Sun J, Liu JH.
Guang Pu Xue Yu Guang Pu Fen Xi. 2009 May;29(5):1323-6. Chinese.
PMID: 19650481 [PubMed - in process]
- A patient with acute myeloblastic leukemia who presented with conus medullaris syndrome and review of the literature.
Olcay L, Arbas BK, Gökçe M.
J Pediatr Hematol Oncol. 2009 Jun;31(6):440-7.
PMID: 19648794 [PubMed - in process]
- Inhibitory role of toll-like receptors agonists in Plasmodium yoelii liver stage development.
Chen J, Xu W, Zhou T, Ding Y, Duan J, Huang F.
Parasite Immunol. 2009 Aug;31(8):466-73.
PMID: 19646211 [PubMed - in process]
- Feasibility of T(2) (*) mapping for the evaluation of hip joint cartilage at 1.5T using a three-dimensional (3D), gradient-echo (GRE) sequence: A prospective study.
Bittersohl B, Hosalkar HS, Hughes T, Kim YJ, Werlen S, Siebenrock KA, Mamisch TC.
Magn Reson Med. 2009 Jul 30. [Epub ahead of print]
PMID: 19645008 [PubMed - as supplied by publisher]
- Detection of coronary artery lesions and myocardial necrosis by magnetic resonance in systemic necrotizing vasculitides.
Mavrogeni S, Manoussakis MN, Karagiorga TC, Douskou M, Panagiotakos D, Bournia V, Cokkinos DV, Moutsopoulos HM.
Arthritis Rheum. 2009 Jul 30;61(8):1121-1129. [Epub ahead of print]
PMID: 19644909 [PubMed - as supplied by publisher]
- Potential side effects of gadolinium-enhanced MRI .
Smith SM, Hoag SD.
Am Fam Physician. 2009 Aug 1;80(3):214. No abstract available.
PMID: 19642251 [PubMed - in process]
- Crystal structure of the ATP-gated P2X(4) ion channel in the closed state.
Kawate T, Michel JC, Birdsong WT, Gouaux E.
Nature. 2009 Jul 30;460(7255):592-8.
PMID: 19641588 [PubMed - indexed for MEDLINE]
- Clinical evaluation of magnetic resonance imaging in coronary heart disease: The CE-MARC study.
Greenwood JP, Maredia N, Radjenovic A, Brown JM, Nixon J, Farrin AJ, Dickinson C, Younger JF, Ridgway JP, Sculpher M, Ball SG, Plein S.
Trials. 2009 Jul 29;10(1):62. [Epub ahead of print]
PMID: 19640271 [PubMed - as supplied by publisher]
- Motexafin gadolinium: a novel radiosensitizer for brain tumors.
Francis D, Richards GM, Forouzannia A, Mehta MP, Khuntia D.
Expert Opin Pharmacother. 2009 Jul 29. [Epub ahead of print]
PMID: 19640206 [PubMed - as supplied by publisher]
- Effect of intravenous gadolinium-DTPA on diffusion tensor MR imaging for the evaluation of brain tumors.
Bae MS, Jahng GH, Ryu CW, Kim EJ, Choi WS, Yang DM.
Neuroradiology. 2009 Jul 28. [Epub ahead of print]
PMID: 19636547 [PubMed - as supplied by publisher]
- Mural Inflammation in Crohn Disease: Location-Matched Histologic Validation of MR Imaging Features.
Punwani S, Rodriguez-Justo M, Bainbridge A, Greenhalgh R, De Vita E, Bloom S, Cohen R, Windsor A, Obichere A, Hansmann A, Novelli M, Halligan S, Taylor SA.
Radiology. 2009 Jul 27. [Epub ahead of print]
PMID: 19635832 [PubMed - as supplied by publisher]
- Juxta-articular myxoma within the suprapatellar pouch masquerading as a ganglion cyst.
Kosty JW, Moore JG.
Orthopedics. 2009 Jul;32(7):527. doi: 10.3928/01477447-20090527-27.
PMID: 19634839 [PubMed - in process]
- The Evolution of Osseous Metaplasia in Localized Cutaneous Nephrogenic Systemic Fibrosis: A Case Report.
Wiedemeyer K, Kutzner H, Abraham JL, Thakral C, Carlson JA, Tran TA, Hausser I, Hartschuh W.
Am J Dermatopathol. 2009 Jul 23. [Epub ahead of print]
PMID: 19633532 [PubMed - as supplied by publisher]
- Lumbar congestive myelopathy mimicking neoplasia without concurrent vascular malformation.
Tsutsumi S, Abe Y, Yasumoto Y, Ito M.
Neurol Med Chir (Tokyo). 2009 Jul;49(7):316-9.
PMID: 19633406 [PubMed - in process]
- Electrocardiographic and cardiac magnetic resonance imaging parameters as predictors of a worse outcome in patients with idiopathic dilated cardiomyopathy.
Hombach V, Merkle N, Torzewski J, Kraus JM, Kunze M, Zimmermann O, Kestler HA, Wöhrle J.
Eur Heart J. 2009 Jul 24. [Epub ahead of print]
PMID: 19633015 [PubMed - as supplied by publisher]
|
Material Safety Data Sheet |
|
1 Identification of substance
- Product details
- Trade name Gadolinium oxide
Pieces
|
2 Composition/Data on components:
- Chemical characterization:
Designation: (CAS#)
Gadolinium oxide (CAS# 12064-62-9), 100%
- Identification number(s):
- EINECS Number: 235-060-9
|
3 Hazards identification
- Hazard designation: · void
- Information pertaining to particular dangers for man and environment
Not applicable
|
4 First aid measures
- After inhalation
Supply fresh air. If required, provide artificial respiration. Keep patient warm. Consult doctor if symptoms persist.
Seek immediate medical advice.
- After skin contact
Instantly wash with water and soap and rinse thoroughly.
Seek immediate medical advice.
- After eye contact
Rinse opened eye for several minutes under running water. Then consult doctor.
- After swallowing Seek medical treatment.
|
5 Fire fighting measures
- Suitable extinguishing agents
Use fire fighting measures that suit the environment.
- Protective equipment:
Wear self-contained breathing apparatus.
Wear full protective suit.
|
6 Accidental release measures
- Person-related safety precautions:
Wear protective equipment. Keep unprotected persons away.
Ensure adequate ventilation
- Measures for environmental protection:
Do not allow material to be released to the environment without proper governmental permits.
- Measures for cleaning/collecting: Collect mechanically.
- Additional information:
See Section 7 for information on safe handling
See section 8 for information on personal protection equipment.
See Section 13 for information on disposal.
|
7 Handling and storage
- Handling
- Information for safe handling:
Keep containers tightly sealed.
Store in cool, dry place in tightly closed containers.
No special precautions necessary if used correctly.
- Information about protection against explosions and fires:
The product is not flammable
- Storage
- Requirements to be met by storerooms and containers:
No special requirements.
- Information about storage in one common storage facility:
Do not store together with acids.
- Further information about storage conditions:
This product is hygroscopic.
Protect from carbon dioxide.
Avoid contact with air / oxygen.
Keep container tightly sealed.
Store in cool, dry conditions in well sealed containers.
|
8 Exposure controls and personal protection
- Additional information about design of technical systems:
Properly operating chemical fume hood designed for hazardous chemicals and having an average face velocity of at least 100 feet per minute.
- Components with critical values that require monitoring at the
workplace:
Not required.
- Additional information: No data
- Personal protective equipment
- General protective and hygienic measures
The usual precautionary measures should be adhered to in handling the chemicals.
Keep away from foodstuffs, beverages and food.
Instantly remove any soiled and impregnated garments.
Wash hands during breaks and at the end of the work.
- Breathing equipment: Use breathing protection with high concentrations.
- Protection of hands: Impervious gloves
- Eye protection: Safety glasses
- Body protection: Protective work clothing.
|
9 Physical and chemical properties:
- General Information
- Form: Lump
- Colour: White
- Smell: Odourless
- Value/Range Unit Method
- Change in condition
- Melting point/Melting range: 2350 ° C
- Boiling point/Boiling range: Not determined
- Sublimation temperature / start: Not determined
- Flash point: Not applicable
- Inflammability (solid, gaseous) Product is not inflammable.
- Ignition temperature: Not determined
- Decomposition temperature: Not determined
- Danger of explosion: Product is not explosive.
- Critical values for explosion:
- Lower: Not determined
- Upper: Not determined
- Steam pressure: Not determined
- Density at 20 ° C 7.407 g/cm³
- Solubility in / Miscibility with
- Water: Insoluble
|
10 Stability and reactivity
- Thermal decomposition / conditions to be avoided:
No decomposition if used and stored according to specifications.
- Materials to be avoided:
Acids
Air
Carbon dioxide
- Dangerous reactions: No dangerous reactions known
- Dangerous products of decomposition: Metal oxide
|
11 Toxicological information
- Acute toxicity:
LD/LC50 values that are relevant for classification:
Oral: LD50: >5000 mg/kg (rat)
Irritation of eyes: mild: 100 mg (rbt)
- Primary irritant effect:
- on the skin: Powder: irritant effect
- on the eye: Powder: irritant effect
- Sensitization: No sensitizing effect known.
- Additional toxicological information:
To the best of our knowledge the acute and chronic toxicity of this substance is not fully known.
No classification data on carcinogenic properties of this material is available from the EPA, IARC, NTP, OSHA or ACGIH.
|
12 Ecological information:
- General notes:
Do not allow material to be released to the environment without proper governmental permits.
Generally not hazardous for water.
|
13 Disposal considerations
- Product:
- Recommendation
Consult state, local or national regulations for proper disposal.
Hand over to disposers of hazardous waste.
Must be specially treated under adherence to official regulations.
- Uncleaned packagings:
- Recommendation:
Disposal must be made according to official regulations.
|
14 Transport information
- Land transport ADR/RID and GGVS/GGVE (cross-border/domestic)
- ADR/RID-GGVS/E Class: None
- Maritime transport IMDG/GGVSea:
- IMDG/GGVSea Class: None
- Air transport ICAO-TI and IATA-DGR:
- ICAO/IATA Class: None
- Transport/Additional information:
Not dangerous according to the above specifications.
|
15 Regulatory information
- Designation according to EC guidelines:
Observe the normal safety regulations when handling chemicals
The product is not subject to identification regulations under EC Directives and the Ordinance on Hazardous Materials (GefStoffV).
- National regulations
- Information about limitation of use:
For use only by technically qualified individuals.
- Water hazard class: Generally not hazardous for water.
|
16 Other information:
Employers should use this information only as a supplement to other information gathered by them, and should make independent judgement of suitability of this information to ensure proper use and protect the health and safety of employees. This information is furnished without warranty, and any use of the product not in conformance with this Material Safety Data Sheet, or in combination with any other product or process, is the responsibility of the user.
|
|
|
and smallest possible average grain sizes for use in Chemical Vapor Deposition (CVD) and Physical Vapor Deposition (PVD) processes including Thermal and Electron Beam (E-Beam) Evaporation, Low Temperature Organic Evaporation, Atomic Layer Deposition (ALD), Metallic-Organic and Chemical Vapor Deposition (MOCVD). Our standard Pieces sizes average in the range of 3 mm, 4 -5 mm, 100 - 150 mm, 1/8" and 1/4". We can also provide Pieces outside this range. We also produce Gadolinium as pellets, tablets,powder, and sputtering target. Oxide compounds are not conductive to electricity. See research below. Other shapes are available by request. 
